Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen, Inc. (Nasdaq: SRZN) is a biotechnology company developing Wnt pathway–modulating therapeutics with a focus on severe eye diseases, and its news flow reflects this ophthalmology and research orientation. Company press releases frequently highlight progress in its retinal disease pipeline, including updates on preclinical data for candidates such as SZN-8141, SZN-8143, and SZN-413, as well as plans related to regulatory milestones like an intended Investigational New Drug (IND) application for SZN-8141.
Investors following SRZN news can expect regular business updates tied to quarterly financial results, where Surrozen discusses research service revenue, operating expenses, and non-cash items alongside narrative commentary on pipeline momentum. These reports often describe how the company is leveraging its Wnt biology expertise and antibody technologies to advance programs in retinal vascular diseases.
Surrozen’s news stream also covers scientific and medical conference activity. The company reports presentations at ophthalmology-focused meetings such as the Association for Research in Vision and Ophthalmology (ARVO), Clinical Trials at the Summit, and various healthcare investor conferences. These announcements may include summaries of preclinical findings on Wnt-mediated retinal vascular repair and regeneration, as well as overviews of next-generation Wnt therapeutics in retinal diseases.
Corporate and governance developments are another recurring theme in SRZN news. Surrozen discloses leadership changes, including appointments to key roles like Chief Financial Officer and Vice President of Clinical Development, and reports inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Updates on intellectual property, such as the issuance of U.S. patents related to its SWAP™ technology for multi-specific Wnt surrogates, and collaboration developments, including changes to related-party research agreements and details of its partnership with Boehringer Ingelheim, also appear in its announcements. For readers tracking SRZN, this news page aggregates these financial, scientific, and corporate updates in one place.
Surrozen, Inc. (Nasdaq: SRZN) announced plans to present a business update on January 13, 2022, at 9 a.m. ET during the 40th J.P. Morgan Healthcare Conference. The virtual presentation will cover advancements in its pipeline, focusing on drug candidates targeting the Wnt pathway for tissue repair and regeneration. Surrozen is developing specific antibodies for various conditions, including inflammatory bowel disease and neurological disorders. The presentation will be accessible via the Company's Investor Relations website.
Surrozen, Inc. (Nasdaq: SRZN) reported its Q3 2021 financial results, marking a pivotal year as the company began trading publicly. Key highlights include plans for Phase 1 clinical trials for SZN-1326 and SZN-043 in 2022, targeting ulcerative colitis and alcoholic hepatitis. Surrozen's cash position improved to $135.4 million, while research and development expenses rose to $10.4 million for Q3 2021 due to increased external costs. Despite this, the company reported a net loss of $14.0 million for the quarter, compared to $8.6 million in Q3 2020.
Surrozen (Nasdaq: SRZN) has presented encouraging data from its liver disease program at The Liver Meeting 2021. The preclinical studies of SZN-043 demonstrated improved liver metabolic function in mice, with promising non-invasive serum markers for Wnt pathway activation and liver regeneration. Highlights include serum alkaline phosphatase increases, indicating target engagement, and an early increase in circulating angiogenin as a potential biomarker for liver regeneration. These findings support Surrozen's progress towards Phase 1 clinical trials.
Surrozen, a biotechnology firm listed on NASDAQ under the ticker SRZN, announced that CEO Craig Parker will speak at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 at 10:00 a.m. ET. The event will be accessible via a live webcast on the Surrozen website, with an archived replay available later.
Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, which is crucial for organ development and regeneration. Their proprietary technology aims to address various degenerative diseases and tissue injuries.
Surrozen, a biotechnology company focused on Wnt pathway modulation, announced that CEO Craig Parker will present at the Stifel 2021 Virtual Healthcare Conference on November 16 at 4:40 p.m. ET. Interested individuals can access the live webcast through the Investors section of Surrozen's website, where a replay will also be available. The company is engaged in developing tissue-specific antibodies aimed at enhancing biological repair mechanisms, targeting diseases like inflammatory bowel disease, hepatitis, and certain neurological disorders. For more details, visit surrozen.com.
Surrozen, Inc. (SRZN) announced encouraging preclinical data supporting the advancement of SZN-1326 for treating inflammatory bowel disease (IBD). Presented during the 2021 United European Gastroenterology Week, the results show significant colonic mucosal healing and epithelial regeneration in various models. SZN-1326 outperformed traditional treatments, indicating its potential as a transformative therapy for conditions like Crohn's disease and ulcerative colitis. The findings emphasize the importance of Wnt signaling in tissue repair. Further studies are planned to explore SZN-1326 in human clinical trials.
Surrozen Inc. (Nasdaq: SRZN) announced the appointment of Elizabeth "Liz" Nguyen as Vice President and Head of Human Resources on September 23, 2021. With over 20 years of HR experience in the biotechnology industry, Nguyen previously held leadership roles at MyoKardia and InterMune. Her expertise is anticipated to enhance Surrozen's organizational development as the company advances its lead programs and broad research pipeline. Craig Parker, CEO, emphasized the timing of her arrival during the company's growth phase.
Surrozen, Inc. has completed its business combination with Consonance-HFW Acquisition Corp., set to commence trading on Nasdaq under the ticker symbols SRZN for common stock and SRZNW for warrants starting August 12, 2021. This merger was approved by the shareholders of both companies, and Surrozen aims to exploit the Wnt pathway for tissue repair. Management, led by CEO Craig Parker, believes this capital infusion will bolster their innovative therapeutic programs.
Surrozen, Inc. has completed its business combination with Consonance-HFW Acquisition Corp., a special purpose acquisition company. The merger was approved by shareholders on August 10, 2021, and will enable Surrozen to trade its shares on Nasdaq under the ticker symbol SRZN and its warrants as SRZNW beginning August 12, 2021. Surrozen aims to unlock therapeutic applications of the Wnt pathway for tissue repair and regeneration, with a management team led by CEO Craig Parker, focusing on developing innovative therapies for serious diseases.
Surrozen Inc. (Nasdaq: SRZN) has announced that CEO Craig Parker will present a company overview and business update at Canaccord Genuity’s 41st Annual Growth Conference on August 12, 2021, at 9:30 a.m. ET. Interested parties can access the live webcast on Surrozen's website, with a replay available afterward.
Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, with applications in inflammatory bowel disease, hepatitis, eye diseases, and more. For further details, visit surrozen.com.